Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

CovaRisk: Validating a Digital Tool for Ovarian Cancer Risk Assessment and Referral (CovaRisk)

10 de noviembre de 2026 actualizado por: Ahmed Kamal Eldin Abbas Attia, Benha University

Bridging Diagnosis and Decision-Making: Retrospective Validation of CovaRisk for Ovarian Malignancy Risk Stratification and Referral Triage

Ovarian cancer is frequently diagnosed at an advanced stage, while its early symptoms are often nonspecific . In women presenting with an adnexal mass, clinicians must integrate clinical symptoms, menopausal status, tumour markers, ultrasound findings, cross-sectional imaging, and hereditary risk when deciding whether a patient requires urgent gynaecologic oncology referral, specialist review, additional imaging, or conservative follow-up . Existing validated tools address individual components of this pathway, but these tools and guideline recommendations are distributed across different resources .

Descripción general del estudio

Descripción detallada

CovaRisk is an application-based clinical decision support tool designed to integrate many diagnostic elements into a stepwise assessment . It combines symptom criteria, age-adjusted CA-125 interpretation, HE4/ROMA, Risk of Malignancy Index (RMI), IOTA Simple Rules, O-RADS ultrasound and MRI classification, selected tumour markers, and hereditary risk information. The tool provides a transparent triage category and guideline-based next steps while directing users to established specialist tools where appropriate. CovaRisk is intended to support, rather than replace, clinical judgement and validated specialist models .This study aims to evaluate the diagnostic accuracy of CovaRisk version 1.0 for identifying ovarian malignancy, including borderline tumours, using final histopathology as the reference standard, and to compare its performance with the Risk of Malignancy Index and O-RADS ultrasound classification in the same cohort .This study will be a single-centre retrospective diagnostic accuracy study of women aged 18 years or older who underwent surgery for an adnexal mass and have final histopathology available. Preoperative information will be entered into the frozen CovaRisk version 1.0 without access to the postoperative histopathology result . CovaRisk classification will be compared with final histology as the reference standard. Diagnostic performance will be assessed using sensitivity, specificity, predictive values, likelihood ratios, receiver operating characteristic curves and area under the curve . CovaRisk will also be compared with RMI and O-RADS ultrasound in the same cohort .The study will provide an objective assessment of whether CovaRisk can accurately identify ovarian malignancy in a real-world hospital population. The findings will guide refinement of the tool and determine whether it is appropriate to proceed to subsequent usability testing and prospective validation.Innovation CovaRisk does not introduce a new biomarker or imaging sign; its innovation lies in integration and implementation. Validated tools currently address separate stages of the diagnostic pathway: CA-125 and age-based triage in primary care , ultrasound characterisation of adnexal masses , standardised imaging risk stratification, and hereditary breast and ovarian cancer risk estimation . To our knowledge, CovaRisk is the first tool to integrate symptom-based, laboratory, imaging and hereditary risk assessment for suspected ovarian cancer into a single, transparent, guideline-based triage pathway , and this study will be the first to validate such an integrated tool in a Saudi population.

In addition to measuring diagnostic accuracy, comparison of CovaRisk recommendations with the pathways actually followed will provide an audit of adherence to guideline-based referral and genetic counselling , information that single-score calculators do not provide. These features are consistent with the recognised role of clinical decision support systems in standardising care and reducing unwarranted variation in clinical decision-making .

Tipo de estudio

De observación

Inscripción (Estimado)

320

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Mohamed Hassan Mohamed, Assistant Professor
  • Número de teléfono: +966573667609
  • Correo electrónico: M_hassan@med.suez.edu.eg

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Método de muestreo

Muestra no probabilística

Población de estudio

Women aged 18 years or older who underwent surgery for an adnexal mass at King Faisal Specialist Hospital & Research Centre, Madinah, Saudi Arabia, between January 2021 and December 2025, and who have final histopathology available. Consecutive eligible cases are identified from operating theatre records and the institutional histopathology database. Included records contain sufficient preoperative information, at least a preoperative ultrasound report or a CA-125 result. Women with previous ovarian cancer are excluded. Data are extracted retrospectively from existing medical records; no participants are recruited or contacted.

Descripción

Inclusion Criteria:

  • Women aged 18 years or older.
  • Surgical treatment for an adnexal mass at the host institution during the defined retrospective study period.
  • Availability of final histopathology.
  • Availability of sufficient preoperative clinical information, including at least a preoperative ultrasound report and CA-125 result, according to the study eligibility definition

Exclusion Criteria:

  • Previous ovarian cancer.

    • Absence of both a preoperative ultrasound report and CA-125 result.
    • Records in which the relevant preoperative information cannot be reliably established.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: RETROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Retrospective Adnexal Mass Diagnostic Cohort

A single retrospective cohort of women aged 18 years or older who underwent surgical treatment for an adnexal mass at King Faisal Specialist Hospital & Research Centre, Madinah. Preoperative clinical, laboratory, imaging, and hereditary risk data are entered into the CovaRisk version 1.0 tool (blinded to final outcomes), and its diagnostic performance is evaluated against final histopathology as the reference standard, alongside comparative assessments using the Risk of Malignancy Index (RMI) and O-RADS ultrasound classification

CovaRisk does not introduce a new biomarker or imaging sign; its innovation lies in integration and implementation. Validated tools currently address separate stages of the diagnostic pathway: CA-125 and age-based triage in primary care , ultrasound characterization of adnexal masses , standardized imaging risk stratification , and hereditary breast and ovarian cancer risk estimation . To our knowledge, CovaRisk is the first tool to integrate symptom-based, laboratory, imaging and hereditary risk assessment for suspected ovarian cancer into a single, transparent, guideline-based triage pathway , and this study will be the first to validate such an integrated tool in a Saudi population.

In addition to measuring diagnostic accuracy, comparison of CovaRisk recommendations with the pathways actually followed will provide an audit of adherence to guideline-based referral and genetic counselling , information that single-score calculators do not provide.

Otros nombres:
  • CovaRisk
  • TOOL
Arm 1: CovaRisk - Diagnostic classification using the CovaRisk version 1.0 tool. Arm 2: Risk of M

This is a retrospective diagnostic accuracy study. These are paired diagnostic assessment methods applied to the same patients, not separate groups receiving different interventions.

CovaRisk does not introduce a new biomarker or imaging sign; its innovation lies in integration and implementation. Validated tools currently address separate stages of the diagnostic pathway: CA-125 and age-based triage in primary care , ultrasound characterization of adnexal masses , standardized imaging risk stratification , and hereditary breast and ovarian cancer risk estimation . To our knowledge, CovaRisk is the first tool to integrate symptom-based, laboratory, imaging and hereditary risk assessment for suspected ovarian cancer into a single, transparent, guideline-based triage pathway , and this study will be the first to validate such an integrated tool in a Saudi population.

In addition to measuring diagnostic accuracy, comparison of CovaRisk recommendations with the pathways actually followed will provide an audit of adherence to guideline-based referral and genetic counselling , information that single-score calculators do not provide.

Otros nombres:
  • CovaRisk
  • TOOL

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Sensitivity of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy, Including Borderline Tumors, Against Final Histopathology
Periodo de tiempo: Single retrospective record review of surgeries performed January 2021 to December 2025

Proportion of women with a histologically confirmed malignant or borderline ovarian tumour who are classified as high-risk by CovaRisk v1.0. CovaRisk is applied to preoperative data already recorded in medical records, without knowledge of the histopathology result. Reported as a percentage with 95% confidence interval.

Single retrospective record review of surgeries performed January 2021 to December 2025
Specificity of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy Against Final Histopathology
Periodo de tiempo: Single retrospective record review of surgeries performed January 2021 to December 2025

•Proportion of women with benign final histopathology who are classified as not high-risk (intermediate, low or information-only) by CovaRisk v1.0. Reported as a percentage with 95% confidence interval.

Single retrospective record review of surgeries performed January 2021 to December 2025

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Positive Predictive Value of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy
Periodo de tiempo: Single retrospective record review of surgeries performed January 2021 to December 2025.

Proportion of women classified as high-risk by CovaRisk v1.0 who have malignant or borderline final histopathology, with 95% confidence interval.

Unit: percentage of participants

Single retrospective record review of surgeries performed January 2021 to December 2025.
Negative Predictive Value of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy
Periodo de tiempo: Single retrospective record review of surgeries performed January 2021 to December 2025

Proportion of women not classified as high-risk by CovaRisk v1.0 who have benign final histopathology, with 95% confidence interval.

Unit: percentage of participants

Single retrospective record review of surgeries performed January 2021 to December 2025

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de diciembre de 2026

Finalización primaria (Estimado)

1 de enero de 2028

Finalización del estudio (Estimado)

1 de junio de 2028

Fechas de registro del estudio

Enviado por primera vez

11 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Publicado por primera vez (Actual)

16 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

The document primarily notes that research data will be stored securely on password-protected institutional systems and accessible only to authorized members of the research team in compliance with data-protection requirements.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir